Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.
Aernoud T L Fiolet, Tjerk S J Opstal, Arend Mosterd...
https://pubmed.ncbi.nlm.nih.gov/33769515/Actively Recruiting
Led by AZ Sint-Jan AV · Updated on 2024-03-08
2770
Participants Needed
19
Research Sites
17 weeks
Total Duration
Researchers are evaluating whether taking a low dose of colchicine daily, alongside standard treatment, can reduce cardiovascular events in patients with coronary artery disease CAD after treatment with percutaneous coronary intervention PCI. This phase III randomized, double-blind, placebo-controlled trial aims to confirm if colchicine helps prevent further incidents in CAD and to identify patients who might benefit most from this treatment. Participants will be randomly assigned to receive either colchicine 0.5 mg or a matching placebo once daily, in addition to their standard care. The trial plans to enroll up to 2770 participants and will continue until 566 primary endpoint events occur. Follow-up includes a clinic visit one month after randomization, then annual visits with additional telephone check-ins every six months. Throughout the study, participants will complete questionnaires and have their health outcomes monitored to assess events like death, heart attacks, strokes, and need for further coronary procedures over 44 months. Researchers will also evaluate patient-reported outcomes including angina frequency, breathlessness, depression, and quality of life. Medication adherence and safety will be closely tracked during scheduled visits and calls.
CONDITIONS
Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention
L
Lisette Van Hove
H
Hélène De Naeyer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AZ Sint-Jan AV
Lead Sponsor
University Hospital, Ghent
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 5 days after PCI
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to approximately 44 months
Participants take colchicine 0.5 mg or placebo orally once daily alongside standard care to help prevent cardiovascular events.
1 visit 1 month after randomisation, then every 12 months
Duration - Up to approximately 44 months
Participants complete telephone visits every 6 months between standard care visits for medication compliance, questionnaires, and outcome assessments.
Telephone visits every 6 months between annual in-person visits
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Aernoud T L Fiolet, Tjerk S J Opstal, Arend Mosterd...
https://pubmed.ncbi.nlm.nih.gov/33769515/Stefan M Nidorf, John W Eikelboom, Charley A Budgeon...
https://pubmed.ncbi.nlm.nih.gov/23265346/David C Tong, Stephen Quinn, Arthur Nasis...
https://pubmed.ncbi.nlm.nih.gov/32862667/Johannes A N Dorresteijn, Frank L J Visseren, Annemarie M J Wassink...
https://pubmed.ncbi.nlm.nih.gov/23574971/Jean-Claude Tardif, Simon Kouz, David D Waters...
https://pubmed.ncbi.nlm.nih.gov/31733140/Emmanuel De Cock, Shakeel Kautbally, Frank Timmermans...
https://pubmed.ncbi.nlm.nih.gov/39233210/Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd...
https://pubmed.ncbi.nlm.nih.gov/32865380/AZ Sint-Jan AV
Lead Sponsor
University Hospital, Ghent
Collaborating Sponsor